Thanks PJV for providing this information, I just did a bit of...

Thanks PJV for providing this information, I just did a bit of research, looks like it was in a Phase 3 open label trial, agree that the numbers are not that impressive for both the PFS and toxicology compared with our interim IDMC feedback. It just shows us the apatite and need for an effective treatment for HER2 Positive breast cancer. In my opinion, the FDA would be hesitant to fast track any drug during interim phase 1 results straight to approval (no matter how good the results look) Phase 2 may be a different story if we continue with impressive results, one could almost say it would be "unethical" not to approve.